Adverse Drug Reaction Classification System

Pharmaceutical Information
Drug Name Ceftazidime
Drug ID BADD_D00399
Description Bacteria possess a cell wall comprising a glycopeptide polymer commonly known as peptidoglycan, which is synthesized and remodelled through the action of a family of enzymes known as "penicillin-binding proteins" (PBPs).[A232920] β-lactam antibiotics, including cephalosporins, are PBP inhibitors that, through inhibition of essential PBPs, result in impaired cell wall homeostasis, loss of cell integrity, and ultimately bacterial cell death.[A232920, A232925, A232930] Ceftazidime is a third-generation cephalosporin with broad-spectrum antibacterial activity, including against some treatment-resistant bacteria such as _Pseudomonas aeruginosa_.[L32935] Ceftazidime was approved by the FDA on July 19, 1985, and is currently available either alone or in combination with the non-β-lactam β-lactamase inhibitor [avibactam] to treat a variety of bacterial infections.[L32935, L32940]
Indications and Usage For the treatment of patients with infections caused by susceptible strains of organisms in the following diseases: lower respiratory tract infections,skin and skin structure infections, urinary tract infections, bacterial septicemia, bone and joint infections, gynecologic infections, intra abdominal infections (including peritonitis), and central nervous system infections (including meningitis).
Marketing Status Prescription; Discontinued
ATC Code J01DD02
DrugBank ID DB00438
KEGG ID D00921
MeSH ID D002442
PubChem ID 5481173
TTD Drug ID D0PH5Z
NDC Product Code 25021-129; 0409-5084; 44567-236; 0409-5093; 10402-013; 0409-5082; 25021-128; 25021-127; 0264-3143; 0409-5092; 44567-237; 52946-0924; 0409-5086; 44567-235; 0264-3145
Synonyms Ceftazidime | Fortaz | Fortum | Ceftazidime Pentahydrate | LY-139381 | LY 139381 | LY139381 | Tazidime | Ceftazidime Anhydrous | Pyridinium, 1-((7-(((2-amino-4-thiazolyl)((1-carboxy-1-methylethoxy)imino)acetyl)amino)-2-carboxy-8-oxo-5-thia-1-azabicyclo(4.2.0)oct-2-en-3-yl)methyl)-, inner salt, pentahydrate, (6R-(6alpha,7beta(Z)))- | GR-20263 | GR 20263 | GR20263
Chemical Information
Molecular Formula C22H22N6O7S2
CAS Registry Number 72558-82-8
SMILES CC(C)(C(=O)O)ON=C(C1=CSC(=N1)N)C(=O)NC2C3N(C2=O)C(=C(CS3)C[N+]4=CC=CC=C4)C(=O)[O -]
Chemical Structure
ADR Related Proteins Induced by Drug
ADR Term Protein Name UniProt AC TTD Target ID PMID
Not AvailableNot AvailableNot AvailableNot AvailableNot Available
ADRs Induced by Drug
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Abdominal pain07.01.05.002--
Acidosis14.01.03.0020.000319%
Agitation19.06.02.001; 17.02.05.012--
Agranulocytosis01.02.03.001--Not Available
Alanine aminotransferase increased13.03.01.003--
Alcohol intolerance14.02.01.001--
Anaemia01.03.02.0010.000213%
Anaphylactic reaction24.06.03.006; 10.01.07.0010.000852%
Anaphylactic shock24.06.02.004; 10.01.07.0020.000426%Not Available
Anaphylactoid reaction24.06.03.007; 10.01.07.0030.000213%Not Available
Angioedema23.04.01.001; 10.01.05.0090.000213%Not Available
Aplastic anaemia01.03.03.002--Not Available
Arrhythmia02.03.02.0010.000056%Not Available
Aspartate aminotransferase increased13.03.01.006--
Asterixis17.01.06.001; 09.01.03.004--Not Available
Blood creatinine increased13.13.01.0040.000213%
Blood lactate dehydrogenase increased13.04.02.002--
Blood urea increased13.13.01.006--Not Available
Body temperature increased13.15.01.001--Not Available
Bronchospasm22.03.01.004; 10.01.03.012--
Cardiac arrest02.03.04.0010.000139%
Cardio-respiratory arrest22.02.06.007; 02.03.04.002--Not Available
Chest discomfort22.02.08.001; 08.01.08.019; 02.02.02.0090.000319%Not Available
Chest pain22.02.08.003; 08.01.08.002; 02.02.02.0110.000319%Not Available
Cholestasis09.01.01.0010.000213%Not Available
Colitis07.08.01.001--
Coma17.02.09.001--Not Available
Confusional state17.02.03.005; 19.13.01.0010.000426%
Death08.04.01.001--
Dermatitis23.03.04.002--Not Available
The 1th Page    1 2 3 4 5    Next   Last    Total 6 Pages